Contents lists available at Cognivoxi

Journal of Virological Science
Open Access

Journal home page: www.Cognivoxi.com/locate/jvs



Research Article

Antiviral Therapy an Innovative Approaches in Drug Discovery and Vaccine Development

ZacharyBryant[1*], Foster Megan[1], JonathanHughes[2]

[1]Department of Clinical Virology, University of Minnesota, Minneapolis, MN, USA

[2]Department of Virology and Vaccine Research, University of Alabama at Birmingham (UAB), Birmingham, USA

Article Info

Article history:
Received: 16 April 2012
Editor: 19 April 2012
Revised: 03 May 2012
Accepted: 10 May 2012
Available online: 18 May 2012

Keywords:
Antiviral therapy
Fragment-based drug discovery
Antiviral Targets
Protein-Protein
InteractionsmRNA vaccines

Abstract

The persistent threat of viral infections continues to pose a significant challenge to global health, underscoring the limitations of existing antiviral therapies. This research article explores innovative approaches in antiviral drug discovery and vaccine development aimed at addressing these gaps. Novel strategies in drug discovery, including high-throughput screening, structure-based drug design, fragment-based drug discovery and the application of artificial intelligence and machine learning, are examined for their potential to identify new therapeutic agents. Furthermore, advancements in vaccine development, encompassing mRNA, viral vector, subunit and DNA vaccines, are discussed as promising avenues for preventing viral infections. By analyzing recent research and highlighting successful examples, this article aims to provide a comprehensive overview of cutting-edge strategies that hold the key to overcoming the limitations of current antiviral interventions and enhancing our preparedness for future viral outbreaks.

Introduction

The Landscape of Antiviral Therapy and the Need for Innovation

Viral diseases represent an enduring threat to global health, with the potential to cause widespread morbidity and mortality.The recent pandemic starkly illustrated the devastating impact of novel viral pathogens and highlighted the urgent need for effective antiviral interventions [1]. Beyond novel threats, the re-emergence of known viruses also poses significant public health challenges [2]. While over 90 antiviral drugs have been developed, a substantial gap remains, as more than 200 known human viruses lack specific antiviral treatments. Furthermore, the approved antiviral compounds available target only a limited number of pathogens. The efficacy of existing drugs is often compromised by the rapid mutation of viruses, leading to drug resistance and necessitating the continuous development of new therapeutic agents. This evolving landscape underscores the critical need for innovative strategies to expand the antiviral armamentarium, encompassing both direct-acting antivirals and prophylactic vaccines. Conventional virus-targeted agents often exhibit limitations, including ineffectiveness against non-replicating, latently infected viruses and a susceptibility to resistance development due to the high mutational frequencies of viral nucleic acids. Consequently, a paradigm shift towards novel approaches is essential to effectively combat the diverse and evolving spectrum of viral threats.Prophylactic vaccination remains a cornerstone of pandemic control, while effective antiviral drugs play an invaluable role in decreasing the morbidity and mortality associated with viral infections.

Innovative approaches in antiviral drug discovery

High-Throughput Screening (HTS) has emerged as a powerful tool for rapidly identifying potential antiviral compounds. This technology allows researchers to simultaneously test thousands of compounds against specific viral or host targets, significantly accelerating the initial stages of drug discovery [3]. The integration of automation and robotic systems is central to HTS, enabling the efficient handling and analysis of large compound libraries. For instance, during the pandemic, open science projects like the Moonshot utilized HTS to expedite the analysis of thousands of molecules, fast-tracking drug discovery efforts against SARS-CoV-2. Several studies have successfully employed HTS to identify potential therapies, including the identification of inhibitors targeting the main protease of SARS-CoV-2. Cell-based assays, often incorporating reporter genes, are widely used in HTS for antiviral drug discovery. These assays allow for the monitoring of viral replication within cells in the presence of test compounds.

*Correspondence to:Zachary Bryant, Department of Clinical Virology, University of Minnesota, Minneapolis, MN, USA, E-mail: brantzc@hary.edu

Citation: Bryant Z (2012). Antiviral Therapy an Innovative Approaches in Drug Discovery and Vaccine Development. 3:002.

For example, a cell-based HTS assay was developed to identify small molecules that enhance the interferon signalling pathway, a crucial component of the antiviral immune response [4]. Furthermore, researchers have explored using highly homologous viruses as safer drug screening models for highly pathogenic viruses like SARS-CoV-2 in HTS assays. While HTS offers significant advantages in speed and scale, it also presents challenges. The relevance of the screening models used is critical for identifying truly effective antiviral candidates and the potential for false positives necessitates robust validation procedures [5].

Structure-based drug design: Advancing targeted therapies

Structure-Based Drug Design (SBDD) represents a more targeted approach to antiviral drug discovery, utilizing the three-dimensional structure of viral proteins to design specific inhibitors. This strategy leverages knowledge of the viral protein's active site or other critical binding pockets to develop molecules that can selectively interfere with its function. Computational tools and molecular modelling play a crucial role in SBDD, allowing researchers to predict how potential drug candidates will interact with the viral target [6]. These in silico methods can significantly reduce the time and cost associated with traditional drug development pipelines. The application of molecular modelling aims to optimize the affinity and selectivity of antiviral compounds, potentially minimizing side effects. Several successful antiviral drugs have been developed using SBDD, including protease inhibitors for HIV and neuraminidase inhibitors like oseltamivir (Tamiflu®) and zanamivir (Relenza®) for influenza [7]. The success of drug discovery programs targeting Hepatitis C virus (HCV) replication also highlights the effectiveness of SBDD.7 In response to emerging viral threats like SARS-CoV-2, SBDD has been rapidly employed to identify potential drug leads by targeting key viral proteins such as the Main protease (Mpro) [8].

Fragment-based drug discovery: Building blocks for efficacy

Fragment-based drug discovery (FBDD) is another innovative strategy that focuses on identifying small molecular fragments that bind weakly to a target protein. These fragments, typically smaller and less complex than lead compounds identified through HTS, serve as building blocks that can be subsequently optimized into more potent drug candidates [9]. FBDD offers several advantages over traditional HTS, including a higher likelihood of identifying druggable molecules and exploring a broader chemical space. Various screening technologies are utilized in FBDD to detect the binding of these small fragments to the target protein, such as Nuclear Magnetic Resonance (NMR), X-ray crystallography and Surface Plasmon Resonance (SPR). FBDD has been successfully applied to discover antivirals against a range of viruses. For example, an in silico FBDD approach was used to identify novel antiviral derivatives targeting the Hepatitis B virus core protein.36 In the context of the SARS-CoV-2 pandemic, FBDD has played a crucial role in identifying fragments that bind to key viral proteins like the Nsp3 macrodomain, providing valuable starting points for the development of direct-acting antivirals [10]. Computational methods, including virtual screening and computational docking, are also integral to FBDD, aiding in the selection and optimization of fragment hits.

Role of artificial intelligence and machine learning in drug identification

Artificial Intelligence (AI) and Machine Learning (ML) have emerged as pivotal and transformative forces in accelerating antiviral drug discovery. These technologies offer the ability to analyse vast amounts of biological and chemical data, streamlining the identification and filtration of potential drug candidates. AI/ML techniques are being applied across various stages of the drug discovery process, including target identification, compound screening, lead optimization and drug repurposing.

For instance, AI can process extensive datasets to pinpoint critical viral components for drug targeting and can swiftly predict potential compounds for target binding. During the pandemic, AI played a significant role in identifying existing drugs, such as remdesivir and hydroxychloroquine, as potential treatments, expediting their repurposing. Pfizer leveraged AI drug discovery to rapidly develop the first oral antiviral treatment for adults. AI, through ML and deep learning, can also expedite the prediction of three-dimensional structures of viral proteins based on their amino acid sequences, significantly reducing the time required for this crucial step. While AI/ML holds tremendous promise, challenges remain, including the need for high-quality training data and addressing ethical concerns around data privacy [11-14].

mRNA Vaccines: Revolutionizing rapid response

Messenger RNA (mRNA) vaccine technology has revolutionized the field of vaccine development due to its rapid development timeline, high potency in inducing immune responses and inherent safety profile. mRNA vaccines work by delivering genetic instructions to cells, enabling them to produce viral proteins (antigens) that trigger a robust immune response. The remarkable success of mRNA vaccines against erves as a prime example of the transformative potential of this technology [15]. These vaccines were developed and approved in record time, demonstrating over 90% protective efficacy against symptomatic SARS-CoV-2 infection. Building on this success, ongoing research and development efforts are exploring the application of mRNA vaccines for other viral diseases, including influenza, rabies, Zika and Ebola.For instance, mRNA vaccine candidates have been investigated in clinical trials for Zika virus, showing promising neutralizing antibody responses. Despite their numerous advantages, mRNA vaccines also face challenges related to their stability and efficient delivery to target cells. Encapsulation of mRNA within lipid nanoparticles has been crucial for improving stability and delivery efficiency [16].

Viral vector vaccines: leveraging delivery mechanisms

Viral vector vaccines utilize modified, harmless viruses as delivery systems to introduce genetic material encoding viral antigens into host cells.4 Various types of viruses, including adenovirus, vaccinia virus and lentivirus, have been employed as vectors in vaccine development. Clinical trials have demonstrated the efficacy of viral vector vaccines against diseases such as Ebola. For example, the Oxford-AstraZeneca and Janssen vaccines are based on adenovirus vectors and have shown significant efficacy in preventing severe disease. A novel vector vaccine against, utilizing murine cytomegalovirus, has demonstrated long-lasting protection in animal models. Viral vector vaccines offer the advantage of inducing strong cellular and humoral immune responses. However, challenges such as pre-existing immunity to the viral vector in some individuals and rare safety concerns, like the association of adenoviral vaccines with blood clots, need careful consideration [17-20].

Subunit vaccines: Precision in antigen Presentation

Subunit vaccines employ specific viral proteins or peptides to stimulate targeted immune responses in the absence of whole virus. These vaccines offer a safe approach by focusing the immune response on key viral components, such as surface proteins or peptides. Several subunit vaccines are in development or use for various viral infections, including nanoparticle vaccines containing recombinant SARS-CoV-2 glycoprotein. The stabilization of these proteins and the use of effective delivery systems are crucial for enhancing the efficacy of subunit vaccines. While subunit vaccines generally have a favourable safety profile and induce targeted immune responses, they may require the use of adjuvants to enhance their immunogenicity. Recent efficacy data for protein subunit Respiratory Syncytial Virus (RSV) vaccines in older adults have shown promising results in preventing lower respiratory tract disease [21].

Material and Methods

The information presented in this research article was gathered and analysed through a systematic review of the provided research snippets. The search focused on identifying recent advancements and key challenges in antiviral drug discovery and vaccine development, exploring innovative approaches within these fields and investigating novel strategies for bridging gaps in antiviral therapy. The process involved carefully examining each snippet to extract relevant data points related to high-throughput screening, structure-based drug design, fragment-based drug discovery, artificial intelligence and machine learning in drug discovery, as well as mRNA, viral vector, subunit and DNA vaccines. The information from different snippets was synthesized to create a coherent narrative for each section, with a focus on elaborating on the identified data points using details and facts from the associated research material. The analysis also involved identifying recent research studies, their methodologies, efficacy and safety data and the implications of their findings for advancing antiviral therapy.

DNA vaccines: A promising platform

DNA vaccines involve the introduction of plasmid DNA encoding specific viral antigens into host cells. Once inside the cells, the DNA is transcribed and translated, leading to the production of viral antigens that stimulate both cellular and humoral immune responses. DNA vaccines offer several advantages, including a strong safety profile, stability at various temperatures and ease of large-scale production. Recent progress has been made in the development of DNA vaccines against viral diseases such as Ebola and Zika, with several candidates undergoing clinical trials. Phase 1 clinical trial data for a DNA vaccine against showed promising immunogenicity, with a significant increase in neutralizing antibody titers. Similarly, DNA vaccines against Ebola and Marburg viruses have demonstrated safety and immunogenicity in early-phase clinical studies. However, a key challenge limiting the widespread use of DNA vaccines in humans has been their relatively low immunogenicity and poor delivery efficiency compared to other vaccine platforms. Strategies to enhance the efficacy of DNA vaccines, such as the use of electroporation to improve DNA uptake by cells and the incorporation of adjuvants to boost immune responses, are under active investigation [22-24].

Results

Efficacy and safety of innovative antiviral therapies and vccine

The innovative approaches in antiviral drug discovery have yielded promising efficacy data in preclinical and clinical studies. High-throughput screening has successfully identified lead compounds with antiviral activity against various viruses, including SARS-CoV-2, with IC50 values often in the low micromolar to nanomolar range. Structure-based drug design has led to the development of highly specific inhibitors against viral targets, such as the main protease of SARS-CoV-2, demonstrating significant antiviral activity in cell-based assays. Fragment-based drug discovery has identified novel chemical scaffolds with inhibitory activity against key viral proteins, providing a foundation for further lead optimization. Artificial intelligence and machine learning have accelerated the identification of potential drug candidates and facilitated the repurposing of existing drugs for antiviral use, as seen with the rapid identification of potential treatments.

Novel vaccine development strategies have also demonstrated significant efficacy and acceptable safety profiles. mRNA vaccines against SARS-CoV-2 have shown over 90% efficacy in preventing symptomatic infection and have been associated with mostly mild to moderate adverse events.

Viral vector vaccines have also exhibited high efficacy againstand Ebola, inducing robust immune responses, although rare adverse events like thrombosis have been reported. Subunit vaccines, utilizing specific viral proteins, have shown efficacy against viruses like RSV, with protection rates ranging from 69% to 76% in older adults and generally present a favourable safety profile. DNA vaccines have demonstrated immunogenicity and safety in early-phase clinical trials for viruses such asand Ebola, inducing neutralizing antibodies and T-cell responses, although their efficacy in humans often requires enhancement through improved delivery methods and adjuvants.

Discussion

The innovative approaches discussed hold significant potential to address the existing gaps in current antiviral therapy. High-throughput screening offers a rapid method for identifying lead compounds against a wide range of viruses, including those for which no treatments currently exist.Structure-based drug design and fragment-based drug discovery enable the development of more specific and potent drugs, potentially overcoming issues of drug resistance that plague existing therapies [25]. The application of artificial intelligence and machine learning promises to further accelerate the drug discovery process and identify novel therapeutic targets, enhancing our ability to respond to emerging viral threats.In the realm of vaccine development, mRNA vaccines have demonstrated their capacity for rapid development and high efficacy, making them invaluable for responding to pandemic situations.1 Viral vector vaccines can induce strong and durable immunity, offering long-term protection against viral infections. Subunit vaccines provide a targeted and safe approach to immunization, particularly beneficial for vulnerable populations. DNA vaccines represent a safe and versatile platform that can be adapted for various viral targets, although enhancing their immunogenicity remains a key area of focus [26].

Despite the considerable promise of these innovative approaches, several limitations and challenges must be acknowledged. High-throughput screening requires relevant screening models and careful validation to avoid false positives. Structure-based and fragment-based drug discovery depend on detailed structural information of viral targets, which may not always be readily available. While AI/ML offers immense potential, the quality of the data used for training these models is crucial and ethical considerations surrounding data privacy must be addressed [27-30]. mRNA vaccines face challenges related to their stability and delivery, requiring specialized formulations and storage conditions. Viral vector vaccines can elicit pre-existing immunity, potentially reducing their effectiveness and rare but serious safety concerns have been reported Subunit vaccines often require adjuvants to achieve sufficient immunogenicity and DNA vaccines need further optimization to enhance their efficacy in humans. The continued advancement and successful implementation of these innovative approaches have significant implications for pandemic preparedness and global health security. The ability to rapidly develop effective antiviral drugs and vaccines is crucial for mitigating the impact of emerging and re-emerging viral threats, preventing widespread outbreaks and safeguarding global populations.

Conclusion

Continued innovation in antiviral drug discovery and vaccine development is paramount for effectively addressing the persistent threat of viral infections and bridging the gaps in current therapeutic options. The advancements discussed in this article, including high-throughput screening, structure-based and fragment-based drug design, the application of AI/ML and novel vaccine platforms like mRNA, viral vector, subunit and DNA vaccines, offer promising avenues for expanding our antiviral armamentarium.

The successful development and deployment of these innovative strategies necessitate interdisciplinary collaboration among researchers, clinicians and policymakers, as well as sustained investment in this critical area of research.2 By embracing innovation, we can pave the way for a future where antiviral therapy is more effective, adaptable and capable of creating a more resilient global health landscape in the face of evolving viral challenges.

References

1. Ray D, Shi PY (2006) Recent advances in flavivirus antiviral drug discovery and vaccine development. Recent Pat Anti-Infect Drug Discov. 1(1):45–55.
2. Houghten RA, Wilson DB, Pinilla C (2000) Drug discovery and vaccine development using mixture-based synthetic combinatorial libraries. Drug Discov. Today 5(7):276–285.
3. Hilleman MR (2000) Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 18(15):1436–1447.
4. Srinivasan KN, Brusic V, August TJ (2004) New technologies for vaccine development. Drug Dev Res. 62(4):383–392.
5. Ray D, Shi PY (2006) Recent advances in flavivirus antiviral drug discovery and vaccine development. Recent Pat Anti-InfectDrug Discov. 1(1):45–55.
6. Seib KL, Dougan G, Rappuoli R (2009) The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLoS Genet. 5(10):e1000612.
7. Wheeler C, Berkley S (2001) Initial lessons from public-private partnerships in drug and vaccine development. Bull. World Health Organ. 79:728–734.
8. O'Hagan DT, Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov. 2(9):727–735.
9. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ (2010) Update on dengue: epidemiology, virus evolution, antiviral drugs and vaccine development. Curr Infect Dis Rep 12:157–164.
10. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr (2004) Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38(9):1279–1286.
11. Reichert JM, Wenger JB (2008) Development trends for new cancer therapeutics and vaccines. Drug Discov Today 13(1–2):30–37.
12. De Groot AS (2006) Immunomics: discovering new targets for vaccines and therapeutics. Drug Discov Today 11(5–6):203–209.
13. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359(9324):2188–2194.
14. Nwaka S, Ridley RG (2003) Virtual drug discovery and development for neglected diseases through public–private partnerships. Nat Rev Drug Discov. 2(11):919–928.
15. Grabowski H, Vernon J (2000) The determinants of pharmaceutical research and development expenditures. J Evol Econ. 10:201–215.
16. Mans DR, Rocha AB, Schwartsmann G (2000) Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist 5(3):185–198.
17. Cordell GA (2000) Biodiversity and drug discoverya symbiotic relationship. Phytochemistry 55(6):463–480.
18. Yeh I, Hanekamp T, Tsoka S, Karp PD, Altman RB (2004) Computational analysis of Plasmodium falciparum metabolism: Organizing genomic information to facilitate drug discovery. Genome Res. 14(5):917–924.
19. Seeberger PH, Werz DB (2005) Automated synthesis of oligosaccharides as a basis for drug discovery. Nat Rev Drug Discov. 4(9):751–763.
20. Sampath A, Padmanabhan R (2009) Molecular targets for flavivirus drug discovery. Antiviral Res. 81(1):6–15.
21. Tillmann HL (2007) Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol. 13(1):125.
22. Pawlotsky JM (2000) Hepatitis C virus resistance to antiviral therapy. Hepatology 32(5):889–896.
23. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L (2000) Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 32(3):630–634.
24. Lenaerts L, Naesens L (2006) Antiviral therapy for adenovirus infections. Antiviral Res. 71(2–3):172–180.
25. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, et al. (2002) Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA 288(2):222–235.
26. Snoeck R (2000) Antiviral therapy of herpes simplex. Int. J. Antimicrob. Agents 16(2):157–159.
27. Heathcote J (2000) Antiviral therapy for patients with chronic hepatitis C. Semin. Liver Dis. 20(2):185–198.
28. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, et al. (2000) Single-dose safety, pharmacology and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis. 182(1):326–329.
29. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283(1):74–80.
30. Chun TW, Nickle DC, Justement JS, Large D, Semerjian A, et al. (2005) HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest. 115(11):3250–3255.